Zydus Cadilla announces Remdac, the cheapest variant of Remdesivir 2020/08/13 09:16:27 Sify.com
Ahmedabad: Zydus Cadilla, the city based pharmaceutical major, has introduced India's cheapest version of Remdesivir. In a drug filing notification, Zydus admitted that its new drug Remdac would be priced at Rs 2,800 ($37.44) per 100 miligram vial. For those unaware, Remdesivir is referred to as a wonder drug that speeds recovery for patients detected of Covid-19. For a world that is yet to find the cure to the pandemic Covid, Remdesivir is an experimental drug that is fast acquired by everyone. In the month of July, the US administration was reported of having almost-bought the global stock of Remdesivir. So far, Hetero Labs, Cipla, Mylan, and Jubilant Life Sciences have managed to roll out copies of Remdesivir in India. Cipla's remdesivir variant priced at $66 or Rs 5,000 entered the market sometime in June. Mylan's variant was introduced at a price of Rs 4,800 per vial. The first copy in Asia was Bangladesh's Beximco Pharmaceuticals that rolled a variant in May. Sadly, the demand for Remdesivir and a profiteering mindset had resulted in vials of Remdesivir selling for Rs 65,000 in India's black-market.
India's cheapest remdesivir is here 2020/08/13 05:23:55 Economic Times India
BENGALURU: Zydus Cadila on Thursday launched the cheapest generic version of Gilead Sciences' antiviral drug remdesivir in India to treat COVID-19 following reports of shortages at hospitals in the world's third-worst hit nation.Zydus has priced it at Rs 2,800 per 100mg vial. It will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients, the company said in a regulatory filing.Officials in some Indian states had a few weeks ago complained of supply issues, but a top executive at drugmaker Cipla Ltd had earlier this week said the supplies were stabilising.Zydus is the fifth company to launch a copy of the antiviral in India after privately held Hetero Labs Ltd, Cipla, Mylan NV and Jubilant Life Sciences Ltd.Gilead has also entered into licensing agreements with Dr.Reddy's Laboratories Ltd and Syngene International Ltd to make remdesivir for distribution in 127 countries, including India.India has reported a daily jump of more than 50,000 coronavirus infections for two weeks, with total cases as of Wednesday at 2.
Mylan N : ROSEN, A GLOBALLY RECOGNIZED FIRM, Reminds Mylan N.V. Investors of Important Deadline in Securities Class Action - MYL | MarketScreener 2020/08/12 19:39:03 MarketScreener
NEW YORK, Aug. 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. between February 16, 2016 and May 7, 2019, inclusive ,… | August 12, 2020
Mylan N : ROSEN, A LONGSTANDING AND TRUSTED FIRM, Reminds Mylan N.V. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – MYL | MarketScreener 2020/08/09 17:16:01 MarketScreener
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. between February 16, 2016 and May 7, 2019, inclusive , of the important August 25, 2020 lead… | August 9, 2020
EpiPen purchasers can't sue PBMs over price hikes as classes: judge 2020/08/06 18:09:54 Reuters
A federal judge has declined to certify four classes of EpiPen purchasers to pursue claims that pharmacy benefit managers' pursuit of rebates and other discounts from Mylan NV caused the allergy medication's price to soar.
Notable earnings before Tuesday's open 2019-05-06
ADNT , AES , AGN , AKRX , AMAG , ARMK , ARRY , ATH , ATKR , AVNS , BCC , BGCP , BLD , BR , BUD , CJ , CLVS , CNHI , CNK , CRL , CROX , CTLT , CWEN , DEA , DF , DNR , DPLO , DXPE , EGRX , EMR , ENR , EXPD , FI , GSKY , GTE , GTX , HAE , HSIC , ICL , IM…
Adamis Pharmaceuticals Is Poised For A Sharp Rebound 2019-04-25
Source: BigCharts Long-suffering shareholders have seemingly thrown in the towel on Adamis ( ADMP ) - again! When will they ever learn? Just over the past year, ADMP has fallen and rebounded many times (see my earlier article) . Interestingly, the stock penetrated a lower technical suppor…